1.77
price up icon5.36%   0.09
pre-market  Pre-market:  1.76   -0.01   -0.56%
loading
Vigil Neuroscience Inc stock is traded at $1.77, with a volume of 131.49K. It is up +5.36% in the last 24 hours and down -26.86% over the past month.
See More
Previous Close:
$1.68
Open:
$1.67
24h Volume:
131.49K
Relative Volume:
0.14
Market Cap:
$78.41M
Revenue:
-
Net Income/Loss:
$-82.60M
P/E Ratio:
-0.8592
EPS:
-2.06
Net Cash Flow:
$-48.61M
1W Performance:
-1.67%
1M Performance:
-26.86%
6M Performance:
-47.94%
1Y Performance:
-46.77%
1-Day Range:
Value
$1.66
$1.81
1-Week Range:
Value
$1.65
$1.94
52-Week Range:
Value
$1.49
$6.06

Vigil Neuroscience Inc Stock (VIGL) Company Profile

Name
Name
Vigil Neuroscience Inc
Name
Phone
857-254-4445
Name
Address
100 FORGE ROAD, WATERTOWN
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
VIGL's Discussions on Twitter

Compare VIGL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VIGL
Vigil Neuroscience Inc
1.77 78.41M 0 -82.60M -48.61M -2.06
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-04-24 Initiated William Blair Outperform
Dec-19-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Oct-18-23 Initiated JMP Securities Mkt Outperform
Mar-31-23 Initiated Mizuho Buy
Sep-16-22 Initiated Wedbush Outperform
Aug-29-22 Initiated H.C. Wainwright Buy
Feb-01-22 Initiated Guggenheim Buy
Feb-01-22 Initiated Jefferies Buy
Feb-01-22 Initiated Morgan Stanley Equal-Weight
Feb-01-22 Initiated Stifel Buy
View All

Vigil Neuroscience Inc Stock (VIGL) Latest News

pulisher
Apr 02, 2025

Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Vigil presents data on oral small molecule program including VG-3927 - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials By Investing.com - Investing.com Australia

Apr 02, 2025
pulisher
Apr 02, 2025

Vigil Neuroscience Presents Data on its Small Molecule - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

Clinical Data Breakthrough: Vigil's New Alzheimer's Drug Targets Both Aβ and Tau Pathologies - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Vigil Neuroscience Reports 2024 Results and Clinical Progress - TipRanks

Apr 02, 2025
pulisher
Mar 31, 2025

Vigil Neuroscience Files Secondary Stock Shelf - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Decline in Short Interest - Defense World

Mar 31, 2025
pulisher
Mar 18, 2025

Vigil Neuroscience (VIGL) to Release Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

H.C. Wainwright cuts Vigil Neuroscience stock target to $14 By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

H.C. Wainwright cuts Vigil Neuroscience stock target to $14 - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

FY2029 Earnings Forecast for VIGL Issued By Wedbush - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

Q1 Earnings Estimate for VIGL Issued By William Blair - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

HC Wainwright Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World

Mar 16, 2025
pulisher
Mar 16, 2025

Wedbush Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

Vigil Neuroscience Inc.: Promising Biomarker Data and Strategic Advancements Justify Buy Rating - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Wedbush Cuts Price Target on Vigil Neuroscience to $13 From $24, Keeps Outperform Rating - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Stifel maintains Buy on Vigil Neuroscience, target at $11 - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

SPY ETF News, 3/13/2025 - The Globe and Mail

Mar 13, 2025
pulisher
Mar 11, 2025

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Vigil Neuroscience To Present At The Stifel 2025 Virtual CNS Forum - MENAFN.COM

Mar 11, 2025
pulisher
Mar 11, 2025

Exclusive CNS Forum: Vigil Neuroscience Reveals Latest Breakthroughs in Neurodegeneration Treatment - StockTitan

Mar 11, 2025
pulisher
Mar 06, 2025

Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely? - Yahoo Finance

Mar 06, 2025
pulisher
Mar 05, 2025

Best Stock to Buy Right Now: Dutch Bros vs. Starbucks - The Globe and Mail

Mar 05, 2025
pulisher
Mar 04, 2025

Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 43.6% - Defense World

Mar 04, 2025
pulisher
Mar 01, 2025

Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 20, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire

Feb 20, 2025
pulisher
Feb 17, 2025

What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register

Feb 17, 2025
pulisher
Feb 16, 2025

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN

Feb 16, 2025
pulisher
Feb 16, 2025

Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat

Feb 16, 2025
pulisher
Feb 14, 2025

abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat

Feb 14, 2025
pulisher
Feb 09, 2025

VIGLVigil Neuroscience, Inc. Latest Stock News & Market Updates - StockTitan

Feb 09, 2025
pulisher
Feb 06, 2025

VIGL Stock Update: Vigil Neuroscience Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Feb 06, 2025
pulisher
Feb 05, 2025

The Attractiveness of Investing In Vigil Neuroscience Inc (VIGL) is Growing - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Are Vigil Neuroscience Inc’shares a good deal? - US Post News

Feb 05, 2025
pulisher
Jan 30, 2025

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan

Jan 30, 2025
pulisher
Jan 27, 2025

Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Vigil Neuroscience shares rise on positive Alzheimer's trial data - MSN

Jan 26, 2025

Vigil Neuroscience Inc Stock (VIGL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):